On Tuesday, 10x Genomics Inc (NASDAQ: TXG) opened higher 3.34% from the last session, before settling in for the closing price of $16.78. Price fluctuations for TXG have ranged from $14.02 to $57.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 35.76%. Company’s average yearly earnings per share was noted 35.26% at the time writing. With a float of $100.14 million, this company’s outstanding shares have now reached $105.04 million.
Let’s determine the extent of company efficiency that accounts for 1259 employees. In terms of profitability, gross margin is 65.89%, operating margin of -28.3%, and the pretax margin is -27.93%.
10x Genomics Inc (TXG) Insider Activity
A key investor’s attitude towards the stock of the Health Information Services industry is another important factor to consider. The insider ownership of 10x Genomics Inc is 17.28%, while institutional ownership is 80.74%. The most recent insider transaction that took place on Aug 22 ’24, was worth 152,053. In this transaction Chief Executive Officer of this company sold 6,749 shares at a rate of $22.53, taking the stock ownership to the 882,467 shares. Before that another transaction happened on Aug 22 ’24, when Company’s See Remarks sold 4,351 for $22.53, making the entire transaction worth $98,027. This insider now owns 345,704 shares in total.
10x Genomics Inc (TXG) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 35.26% per share during the next fiscal year.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Check out the current performance indicators for 10x Genomics Inc (TXG). In the past quarter, the stock posted a quick ratio of 4.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.33. Likewise, its price to free cash flow for the trailing twelve months is 80.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
Looking closely at 10x Genomics Inc (NASDAQ: TXG), its last 5-days average volume was 1.96 million, which is a jump from its year-to-date volume of 1.7 million. As of the previous 9 days, the stock’s Stochastic %D was 84.73%. Additionally, its Average True Range was 1.06.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 30.91%, which indicates a significant decrease from 99.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.98% in the past 14 days, which was lower than the 85.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.61, while its 200-day Moving Average is $27.13. However, in the short run, 10x Genomics Inc’s stock first resistance to watch stands at $17.68. Second resistance stands at $18.03. The third major resistance level sits at $18.69. If the price goes on to break the first support level at $16.67, it is likely to go to the next support level at $16.01. Should the price break the second support level, the third support level stands at $15.66.
10x Genomics Inc (NASDAQ: TXG) Key Stats
There are currently 120,491K shares outstanding in the company with a market cap of 2.10 billion. Presently, the company’s annual sales total 618,730 K according to its annual income of -255,100 K. Last quarter, the company’s sales amounted to 151,650 K and its income totaled -35,750 K.
